alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › aggregation-inhibitors

aggregation-inhibitors

6 studies tagged aggregation-inhibitors, dated 2013-09-26 to 2024-06-01. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Liposome nanoparticle conjugation and cell penetrating peptide sequences (CPPs) enhance the cellular delivery of the tau aggregation inhibitor RI-AG03 2024-06-01
  2. Neuroprotection of Cholinergic Neurons with a Tau Aggregation Inhibitor and Rivastigmine in an Alzheimer's-like Tauopathy Mouse Model 2024-04-06
  3. Site-specific amino acid D-isomerization of Tau R2 and R3 peptides changes the fibril morphology, resulting in attenuation of Tau aggregation inhibitor potency 2023-02-26

Studies

6 studies carry this tag.

Date range

2013 to 2024

Top journals

  • Biochemical and biophysical research communications 1
  • Cells 1
  • Chembiochem : a European journal of chemical biology 1
  • Journal of cellular and molecular medicine 1
  • The Journal of biological chemistry 1

6 journals in all.

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Liposome nanoparticle conjugation and cell penetrating peptide sequences (CPPs) enhance the cellular delivery of the tau aggregation inhibitor RI-AG03

    ✓ Peer-reviewed alzhub usefulness score 45 out of 100. Journal of cellular and molecular medicine 2024-06-01 Drug development

    Given the pathological role of Tau aggregation in Alzheimer's disease (AD), our laboratory previously developed the novel Tau aggregation inhibitor peptide, RI-AG03.

  2. Neuroprotection of Cholinergic Neurons with a Tau Aggregation Inhibitor and Rivastigmine in an Alzheimer's-like Tauopathy Mouse Model

    ✓ Peer-reviewed alzhub usefulness score 45 out of 100. Cells 2024-04-06 Drug development

    Recent evidence suggests that tau protein is a putative target for the treatment of dementia, and the tau aggregation inhibitor, hydromethylthionine mesylate (HMTM), has emerged as a potential disease-modifying treatment.

  3. Site-specific amino acid D-isomerization of Tau R2 and R3 peptides changes the fibril morphology, resulting in attenuation of Tau aggregation inhibitor potency

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Biochemical and biophysical research communications 2023-02-26 Drug development

    Tau, a microtubule-binding protein, is a major component of neurofibrillary tangles in the brains of Alzheimer's disease patients.

  4. Oral Tau Aggregation Inhibitor for Alzheimer's Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate

    ✓ Peer-reviewed alzhub usefulness score 74 out of 100. The journal of prevention of Alzheimer's disease 2022-01-01 Drug development

    If the primary end points are met, the data will provide confirmatory evidence of the clinical and biomarker benefits of hydromethylthionine mesylate in minimal to moderate AD.

  5. Potent Tau Aggregation Inhibitor D-Peptides Selected against Tau-Repeat 2 Using Mirror Image Phage Display

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Chembiochem : a European journal of chemical biology 2021-09-12 Drug development

    Alzheimer's disease and other Tauopathies are associated with neurofibrillary tangles composed of Tau protein, as well as toxic Tau oligomers.

  6. Structural determinants of Tau aggregation inhibitor potency

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. The Journal of biological chemistry 2013-09-26 Drug development

    Small-molecule Tau aggregation inhibitors are under investigation as potential therapeutic agents against Alzheimer disease.

All topic tags with their study counts